ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

10:00AM-10:50AM: Abstract Number: 1454

B Cell-specific TLR7 Regulates Lupus in TLR9 Deficient Mice

B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1452–1456)

10:00AM-10:50AM: Abstract Number: 1456

Exploring the RA Bone Marrow Niche by Single-cell Technology to Identify Long Lived ACPA+ Plasma Cells

B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1452–1456)

10:00AM-10:50AM: Abstract Number: 1455

Functional Characterization of PLCG2 Mutations Found in Subjects with Autoinflammation and PLCG2-Associated Antibody Deficiency and Immune Dysregulation (APLAID) Reveals Both Hypermorphic and Hypomorphic Mutants

B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1452–1456)

10:00AM-10:50AM: Abstract Number: 1461

Implementation, Feasibility and Acceptability of Take Charge, an Email Series to Increase Knowledge of Lupus Self-Management Skills

Clinical Practice II (1457–1461)

10:00AM-10:50AM: Abstract Number: 1479

Long-Term Effectiveness of Canakinumab in Autoinflammatory Diseases – Interim Analysis of the CAPS Subgroup from the RELIANCE Registry

Miscellaneous Rheumatic & Inflammatory Diseases II: Evaluating Drug Therapies for COVID-19 (1477–1481)

10:00AM-10:50AM: Abstract Number: 1458

Slower Current Walking Speed Is Associated with Progression in Radiographic Knee Osteoarthritis: The Johnston County Osteoarthritis Project

Clinical Practice II (1457–1461)

10:00AM-10:50AM: Abstract Number: 1459

The Association of Frequent Knee Bending with Trajectories of Pain and Physical Function over 8 Years in Knee Osteoarthritis

Clinical Practice II (1457–1461)

10:00AM-10:50AM: Abstract Number: 1452

Transcriptomic Meta-analysis Reveals a Core Transcriptional Program in Murine B Cell Anergy and Implicates Immunometabolic Regulation as a Central Pathway in Maintaining Non-responsiveness of Autoreactive B-cells in Both Mouse and Man

B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1452–1456)

10:00AM-10:50AM: Abstract Number: 1457

Two Minute Walking Distance and Other Timed Function Tests Are Superior to MMT-8 in Assessing Outcomes in Polymyositis and Dermatomyositis

Clinical Practice II (1457–1461)

11:30AM-1:00PM: Abstract Number: 1445

Citrulline Reactive B Cells Are Present in the Lungs of Risk RA and Early Untreated RA

Plenary Session III (1441–1446)

11:30AM-1:00PM: Abstract Number: 1444

Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The Results of the TICOSPA Trial

Plenary Session III (1441–1446)

11:30AM-1:00PM: Abstract Number: 1442

Denosumab versus Oral Bisphosphonate for Osteoporosis in Long-term Glucocorticoid Users: A 12-month Randomized Controlled Trial

Plenary Session III (1441–1446)

11:30AM-1:00PM: Abstract Number: 1441

Effects of Belimumab on Renal Outcomes, Overall SLE Control and Biomarkers: Findings from a Phase 3, Randomized, Placebo-controlled 104-week Study in Patients with Active Lupus Nephritis

Plenary Session III (1441–1446)

11:30AM-1:00PM: Abstract Number: 1443

High-dimensional Analyses of Checkpoint-inhibitor Related Arthritis Synovial Fluid Cells Reveal a Unique, Proliferating CD38hi Cytotoxic CD8 T Cell Population Induced by Type I IFN

Plenary Session III (1441–1446)

11:30AM-1:00PM: Abstract Number: 1446

Pregnancy Outcomes in Patients with Interstitial Lung Disease

Plenary Session III (1441–1446)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].